Wakabayashi N, Watanabe S, Takeuchi S, Tsuchikawa T, et al. Factors and predictors affecting late external dose rates and isolation period in patients after lutetium-177-labeled DOTA-Tyr3-octreotate treatment for neuroendocrine tumors. Ann Nucl Med 2025;39:696-706.
PMID: 40186742